Nanotechnology-Based Drug Delivery Systems for Lung Cancer: A Focused Review on Nanocarrier Platforms

Abstract

Lung cancer remains the leading cause of cancer mortality worldwide, largely due to late diagnosis, aggressive

progression, and the limited effectiveness of conventional chemotherapies. Systemic agents such as paclitaxel, cisplatin, and

docetaxel suffer from poor solubility, rapid clearance, nonspecific distribution, and dose-limiting toxicity, underscoring the

need for more efficient delivery strategies. Recent advances in nanotechnology have introduced versatile drug delivery systems

capable of enhancing drug stability, improving tumor accumulation, and enabling controlled and sustained release. This review

provides a focused overview of major nanocarrier platforms, polymeric nanoparticles, lipid-based systems, inorganic

nanomaterials, and hybrid nano systems, used to improve chemotherapeutic delivery in lung cancer. Their key material

properties, drug-loading capabilities, and therapeutic advantages are summarized to highlight how nanotechnology can address

the limitations of traditional treatments.